Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal suppositories aim to ease chronic pelvic pain in men

NCT ID NCT07685847

Symptom relief Sponsor: S&R Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Sep 04, 2026 · Updated 3 times

Summary

This study tests whether Prospidol, a rectal suppository containing natural ingredients like hyaluronic acid and Boswellia extract, can reduce pain and urinary symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Forty adult men will use one suppository daily for 10 days each month over three months. Researchers will measure pain scores, urinary function, and quality of life to see if the treatment provides meaningful relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Prospidol suppository (sodium hyaluronate, Boswellia serrata extract, mallow extract, rice bran oil, Eugenia caryophyllus essential oil)
What this could lead to
If effective, Prospidol could offer a non-drug option to reduce pelvic pain and improve quality of life for men with chronic prostatitis.
What could go wrong
This is a small, early-stage study with no placebo group, so results may not prove the treatment works better than natural recovery. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Sep 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * male subjects aged between 18 and 60; * clinical presentation typical of prostatitis and a clinical diagnosis of chronic prostatitis type IIIa or IIIb (CP/CPPS) for at least 3 months; * no treatment for at least 2 months; * PSA \< 3 ng/mL; * digital rectal examination negative for nodules or BPH; * negative microbiological tests on urine and seminal fluid; * baseline score on the validated Italian version of the NIH-CPSI pain domain questionnaire \> 7 or total NIH-CPSI score \> 15; * digital rectal examination not suggestive of prostate cancer. Exclusion Criteria: * patients with signs of infection and a PSA level \> 3 ng/ml; * other active prostate conditions; * patients with active neoplastic, neurodegenerative or immunological conditions, those who are immunocompromised, or those who are already taking supplements or functional foods for any reason; * patients undergoing treatment with systemic or topical corticosteroids; * patients who will not sign the informed consent form; * patients unable to participate in a clinical trial for any reason (e.g. psychiatric patients, those with cancer, on dialysis, or with severe liver or kidney failure); * patients with allergies to any of the components of the medical device (MD) under investigation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic prostatitis prostatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS)

Contacts and locations

Locations

  • Papa Giovanni XXIII Hospital

    Bergamo, Bergamo, 24127, Italy

  • San Giuseppe Moscati Hospital

    Avellino, Avellino, 83100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.